How do you counsel on the risks vs benefits for patients with a strong indication for SGLT2-i and a history of either pyelonephritis or recurrent urinary tract infections?

Would you continue a patient on an SGLT2-inhibitor who has a strong indication for you if they had recurrent simple cystitis?

• Yes, the benefit outweighs the risk
• Yes, new data suggests the relationship between SGLT2-i's and UTIs is weak
• Maybe, depending on the indication
• No, the risks outweigh the benefits
• Other